Skip to main
  1. Stocks
  2. Edgewise Therapeutics
  3. Forecast
EWTX

Edgewise Therapeutics (EWTX) Stock Forecast & Price Target

Edgewise Therapeutics (EWTX) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 63%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Edgewise Therapeutics is attractive because the Servier transaction delivered $1.55 billion upfront and up to $2.65 billion total potential consideration, leaving the company with $1.7 billion in cash and runway into the early 2030s while it advances a focused cardiovascular strategy. The core bull case is EDG-7500, which in the 53-patient, 12-week Phase 2 CIRRUS-HCM Part D study showed meaningful improvements across hemodynamic, biomarker, symptom, and functional endpoints, including about 55% and 51% LVOT gradient reductions and a roughly 65% NT-proBNP decline, with no LVEF below 50% across more than 240 exposed individuals and over 700 echocardiograms. That combination of preserved systolic function, potential for lighter monitoring, and Phase 3 initiation guidance in YE26 supports differentiation versus existing cardiac myosin inhibitors, while EDG-15400 and EDG-003 add longer-dated pipeline optionality.

Bears say

Edgewise Therapeutics is a clinical-stage biopharmaceutical company with limited validated revenue-generating assets, so its value still depends on programs like Sevasemten and EDG-7500 successfully advancing through costly, uncertain development. The bear case is strengthened by regulatory risk around accelerated approval, possible REMS or echo monitoring requirements, and the need for larger, longer studies beyond the current 53-patient, 12-week dataset, which could delay commercialization and dilute differentiation. Competitive pressure from established CMIs such as mavacamten and aficamten, along with likely additional financing needs if the Servier transaction stalls or Phase 3 costs rise, further undermines the fundamental outlook.

Edgewise Therapeutics (EWTX) has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 63% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Edgewise Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Edgewise Therapeutics (EWTX) Analyst Forecast & Price Prediction

Get the latest Edgewise Therapeutics (EWTX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Edgewise Therapeutics (EWTX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Edgewise Therapeutics (EWTX) Forecast

Analysts have given Edgewise Therapeutics (EWTX) a Buy based on their latest research and market trends.

According to 8 analysts, Edgewise Therapeutics (EWTX) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $52.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $52.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Edgewise Therapeutics (EWTX)


Edgewise Therapeutics (EWTX) Analyst Forecast & Price Prediction

Get the latest Edgewise Therapeutics (EWTX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Edgewise Therapeutics (EWTX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover EWTX stock data and trends